V3V Stock Overview
Engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
VITA 34 AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.28 |
| 52 Week High | €5.90 |
| 52 Week Low | €3.69 |
| Beta | 0.63 |
| 1 Month Change | -0.47% |
| 3 Month Change | -6.14% |
| 1 Year Change | -15.08% |
| 3 Year Change | -72.83% |
| 5 Year Change | -66.69% |
| Change since IPO | -66.61% |
Recent News & Updates
Recent updates
Why We're Not Concerned About VITA 34 AG's (ETR:V3V) Share Price
Apr 04
Revenues Tell The Story For VITA 34 AG (ETR:V3V) As Its Stock Soars 26%
Dec 24Is VITA 34 (ETR:V3V) Using Too Much Debt?
Nov 23Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?
Jul 15Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?
Feb 17Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?
Apr 08VITA 34 AG's (ETR:V3V) CEO Compensation Looks Acceptable To Us And Here's Why
Dec 07Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?
May 12Earnings Miss: VITA 34 AG Missed EPS By 29% And Analysts Are Revising Their Forecasts
Apr 03VITA 34 AG's (ETR:V3V) Intrinsic Value Is Potentially 56% Above Its Share Price
Mar 25Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?
Mar 10Here's Why VITA 34 (ETR:V3V) Can Manage Its Debt Responsibly
Feb 22Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?
Feb 05Can Mixed Financials Have A Negative Impact on VITA 34 AG's 's (ETR:V3V) Current Price Momentum?
Jan 18Did You Participate In Any Of VITA 34's (ETR:V3V) Fantastic 201% Return ?
Jan 02How Is VITA 34's (ETR:V3V) CEO Compensated?
Dec 18Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?
Dec 01
Shareholder Returns
| V3V | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -4.5% | -1.1% | -1.4% |
| 1Y | -15.1% | 19.1% | 8.0% |
Return vs Industry: V3V underperformed the German Healthcare industry which returned 21.3% over the past year.
Return vs Market: V3V underperformed the German Market which returned 8.1% over the past year.
Price Volatility
| V3V volatility | |
|---|---|
| V3V Average Weekly Movement | 4.4% |
| Healthcare Industry Average Movement | 4.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: V3V has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: V3V's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 783 | Jakub Baran | www.vita34.de |
VITA 34 AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties.
VITA 34 AG Fundamentals Summary
| V3V fundamental statistics | |
|---|---|
| Market cap | €74.61m |
| Earnings (TTM) | €2.58m |
| Revenue (TTM) | €80.64m |
28.9x
P/E Ratio0.9x
P/S RatioIs V3V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V3V income statement (TTM) | |
|---|---|
| Revenue | €80.64m |
| Cost of Revenue | €51.08m |
| Gross Profit | €29.56m |
| Other Expenses | €26.98m |
| Earnings | €2.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 36.66% |
| Net Profit Margin | 3.20% |
| Debt/Equity Ratio | 26.1% |
How did V3V perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 16:16 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
VITA 34 AG is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emily Haines | First Berlin Equity Research GmbH |
| Tim Kruse | Montega AG |
| IGOR KIM | Oddo Seydler |